The pathogenesis of diabetic retinopathy (DR) consists of a complex patch-work of factors correlated and independent on one another at the same time. It is therefore difficult to find pharmaceuticals able to produce different, or even mutually contrasting effects. Another difficulty are the intrinsic characteristics of the disease which after developing to a "critical" stage, evolves with independent mechanism to the most advanced stages. In spite of that, a great deal of medicaments has been suggested so far, all providing therapeutical logic to interfere with one or more pathogenetical stages of the lesions. Although several clinical trials have been performed, survey and follow-up are still limited and insufficient to draw conclusion on the effectiveness of medical therapy. In recent times new types of medicaments such as aldose-reductase inhibitors and carbonic anhydrase-inhibitors have been suggested. The preliminary results present encouraging perspectives for their use, although caution, until long-term results are available with greater surveys and longer follow-up periods, is advised.
|Translated title of the contribution||Medical treatment of diabetic retinopathy|
|Number of pages||7|
|Journal||Recenti Progressi in Medicina|
|Publication status||Published - Feb 1990|
ASJC Scopus subject areas